Economic Value of Improved Accuracy for Self-Monitoring of Blood Glucose Devices for Type 1 and Type 2 Diabetes in England

McQueen, R. Brett; Breton, Marc D.; Craig, Joyce; Holmes, Hayden; Whittington, Melanie D; Ott, Markus; Campbell, Jonathan D.

doi:10.1177/1932296818769098

Cited by 10 publications

(7 citation statements)

References 34 publications

(62 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For the lifetime analysis, we extrapolated the findings from ASK and routine screening over the projected lifetime of patients using an adaptation from a previously published Markov simulation model (Excel 2016; Microsoft Corporation, Redmond, WA) (28,29). The Markov simulation model estimates long-run clinical and economic outcomes for the average patient with type 1 diabetes (Supplementary Material).…”

Section: Lifetime Analysesmentioning

confidence: 99%

Cost and Cost-effectiveness of Large-scale Screening for Type 1 Diabetes in Colorado

et al. 2020

View full text Add to dashboard Cite

To assess the costs and project the potential lifetime cost-effectiveness of the ongoing Autoimmunity Screening for Kids (ASK) program, a large-scale, presymptomatic type 1 diabetes screening program for children and adolescents in the metropolitan Denver region. RESEARCH DESIGN AND METHODSWe report the resource utilization, costs, and effectiveness measures from the ongoing ASK program compared with usual care (i.e., no screening). Additionally, we report a practical screening scenario by including utilization and costs relevant to routine screening in clinical practice. Finally, we project the potential costeffectiveness of ASK and routine screening by identifying clinical benchmarks (i.e., diabetic ketoacidosis [DKA] events avoided, HbA 1c improvements vs. no screening

show abstract

Section: Lifetime Analysesmentioning

confidence: 99%

Cost and Cost-effectiveness of Large-scale Screening for Type 1 Diabetes in Colorado

et al. 2020

View full text Add to dashboard Cite

show abstract

“…These costs involve direct costs for acute MI, direct costs for follow-up (first year), and direct costs for successfully treated MI. Latest available data for these diabetes-related costs were retrieved from the following references: France, [21][22][23][24] Germany, 25,26 Italy, [27][28][29] Spain, [30][31][32][33][34][35][36] and the United Kingdom [37][38][39][40][41][42][43] (summarized in Table 1).…”

Section: Methodsmentioning

confidence: 99%

“…National and international publications provided the current values of expenditures for both fatal and nonfatal MI events. 20,22,23,28,31,32,38,39,42,43 According to fatal MI events in the diabetic population, fatal MI events were estimated for insulin-treated patients. Costs for fatal and nonfatal MI events were calculated as acute treatment costs and successfully treated (acute treatment costs summed with the first-year follow-up costs).…”

Section: Myocardial Infarctionmentioning

confidence: 99%

Budget Impact of Improved Diabetes Management by Utilization of Glucose Meters With a Color-Range Indicator—Comparison of Five European Healthcare Systems

Fritzen¹,

Basinska

Stautner³

et al. 2019

J Diabetes Sci Technol

View full text Add to dashboard Cite

Background and Aim: Costs for the treatment of diabetes and its comorbidities are a major international issue. A recent randomized clinical trial showed that the introduction of color range indicator (CRI)-based glucose meters (GMs) positively affects the HbA1c of patients with type 1 and type 2 diabetes, when compared to GMs without a CRI. This budget impact analysis aimed to translate this beneficial effect of CRI-based GMs, OneTouch Verio Flex and OneTouch Verio, into potential monetary impact for the healthcare systems of five European countries, Germany, Spain, Italy, France, and the United Kingdom. Material and Methods: Data from a randomized controlled trial, evaluating the effect of CRI-based GMs, were used to estimate the ten-year risk of patients for fatal myocardial infarction (MI) as calculated by the UK Prospective Diabetes Study (UKPDS) risk engine. On the basis of assessed risks for MI, the potential monetary impact for the healthcare systems in five European countries was modeled. Results: Based on a mean HbA1c reduction of 0.36%, as demonstrated in a randomized controlled trial, the UKPDS risk engine estimated a reduction of 2.4% of the ten-year risk of patients for fatal MI. When applied to our economic model, substantial potential cost savings for the healthcare systems of five European countries were calculated: €547 472 (France), €9.0 million (Germany), €6.0 million (Italy), €841 799 (Spain), and €421 069 (United Kingdom) per year. Conclusion: Improving metabolic control in patients with diabetes by the utilization of CRI-based GMs may have substantial positive effects on the expenditure of the healthcare systems of several European countries.

show abstract

“…26,27 Average cost for hypoglycemia included costs for hospitalized and ambulant treated patients. [38][39][40][41][42][43][44][45][46] The percentage of hospitalized patients were multiplied by the average costs of hospitalization and summed with percentage of ambulance-treated patients multiplied by average ambulance costs. UKPDS Risk Engine (55).…”

Section: No Tests Day X Price Of Strip X Price Of Lancet Days Price Gmmentioning

confidence: 99%

Pan-European Economic Analysis to Identify Cost Savings for the Health Care Systems as a Result of Integrating Glucose Monitoring Based Telemedical Approaches Into Diabetes Management

Fritzen¹,

Basinska

Rubio-Almanza

et al. 2019

J Diabetes Sci Technol

View full text Add to dashboard Cite

Background: Self-monitoring of blood glucose supported by the diabetes-app OneTouch Reveal® has demonstrated to improve HbA1c. We aimed at analyzing costs savings related the integration of telemedical features into diabetes management. Methods: Data from a randomized controlled trial were used to assess the 10-year risk of patients for fatal myocardial infarction (MI). On the basis of this risk assessments—also related to a 5% or 10% reduction of hypoglycemic episodes—cost savings for the health care systems of five European countries—France, Germany, Italy, Spain, and the United Kingdom—were modeled. Results: HbA1c reduction of 0.92% in insulin-treated type 2 diabetes patients (T2DM) was associated with a 2.3% decreased 10-year risk for fatal MI. In combination with a 10% reduction of hypoglycemic events this risk reduction led to cost savings of €16.1 million (France), €57.8 million (Germany), €30.9 million (Italy), €23.8 million (Spain), and €5.8 million (UK), considering all insulin-treated T2DM patients in the respective countries. Conclusion: Improving metabolic control and thus risk for comorbidities like MI by combining the glucose meter with CRI with telemedical features has the potential to reduce costs for European health care systems.

show abstract

Economic Value of Improved Accuracy for Self-Monitoring of Blood Glucose Devices for Type 1 and Type 2 Diabetes in England

Abstract: Investment in devices with higher strip prices but improved accuracy (less error) appears to be an efficient strategy for insulin-treated diabetes patients at high risk of severe hypoglycemia.

Cited by 10 publications

References 34 publications

Cost and Cost-effectiveness of Large-scale Screening for Type 1 Diabetes in Colorado

Cost and Cost-effectiveness of Large-scale Screening for Type 1 Diabetes in Colorado

Budget Impact of Improved Diabetes Management by Utilization of Glucose Meters With a Color-Range Indicator—Comparison of Five European Healthcare Systems

Pan-European Economic Analysis to Identify Cost Savings for the Health Care Systems as a Result of Integrating Glucose Monitoring Based Telemedical Approaches Into Diabetes Management

Contact Info

Product

Resources

About